Beamtree Holdings Ltd · ASX:BMT
Beamtree — H1 FY2022 Earnings Presentation
30 slides from Beamtree's earnings presentation, Feb 15, 2022
Slide 1: Half Yearly Investor Presentation
Half Yearly Investor Presentation 15 February, 2022
Slide 2: Agenda
Agenda Chair’s Address • FY22 Highlights to date Management Update • Potential(x) Integration Update • Strategy and Growth Financial Summary – 1H FY22 Q&A Copyright © Beamtree Holdings Limited – All Rights Reserved 1
Slide 3: Michael Hill, Non-Executive Chairman
Michael Hill Non-Executive Chairman Copyright © Beamtree Holdings Limited – All Rights Reserved 2
Slide 4: Tim Kelsey, Chief Executive Officer and management
Tim Kelsey Chief Executive Officer Duane Attree Cheryl McCullagh Cassandra Chen Chief Commercial and Development Officer Chief Strategy Officer (Global) Chief Financial Officer
Slide 5: Financial Summary 1H FY22
Financial Summary 1H FY22 Growth and investment was the focus for the first half of FY22, despite ongoing challenges presented by the COVID-19 pandemic. Thanks to strong revenue performance and excellent customer retention rates, we were able to make significant investments across the business withi
Slide 6: Highlights of FY22
Highlights of FY22 Copyright © Beamtree Holdings Limited – All Rights Reserved 5
Slide 7: Supporting healthcare providers globally
Supporting healthcare providers globally 50m+ people supported by Beamtree implementations every year 1000+ 155+ 705+ 4 23 140+ Hospitals Labs Hospitals Continents Countries Customers
Slide 8: Beamtree has seen continued growth in the first half of FY22
Beamtree has seen continued growth in the first half of FY22 Key acquisition of Potential(x) making Beamtree Australia’s largest health data and AI decision support platform. Ai Key acquisition of Ainsoff to drive AI product innovation. 100% of our retention and renewal goals for the first half of F
Slide 9: Beamtree mobi
Beamtree mobi
Slide 10: The problems we solve
the problems we solve The best health services deliver value for money by reducing avoidable mortality, waste, length of stay, readmissions and cost of care. Complications are costly. One in nine patients who go to hospital suffer a complication, which costs Australian hospitals more than A$5 billio
Slide 11: How we create value: the Learning Health System
How we create value: the Learning Health System Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency. Return knowledge to Collect health the rules engine information Support clinicians Encode in standard coders and formats administrators
Slide 12: Data, insights and action for better healthcare
Data, insights and action for better healthcare Our solutions and services help clients make the best use of their data. From improving the quality of the inputs, to better visualising the outputs and automating decisions, we help healthcare providers make informed decisions and improve patient outc
Slide 13: Beamtree and Potential(x) Integration Rationale
Beamtree and Potential(x) Integration Rationale Accelerate growth in new global markets and adjacent sectors Add value and market access for existing solutions and software Reduce barriers to entry in ANZ market Immediate market share, expertise and insight into public hospital sector Grow our peopl
Slide 14: Beamtree and Potential(x) Integration Update
Beamtree and Potential(x) Integration Update To identify and action efficiencies in the organisational ways of working, value-creation, cost containment and avoidance, and organisation and operational alignment. The first 100 days of the PMI finished on track with nearly 60% of the overall integrati
Slide 15: Beamtree is creating next-generation solutions
Beamtree is creating next-generation solutions to enable the Clinical and Informatics Users • RippleDown Decision Support • Automating safety alerts • Practice Analytics Organisation • Automated Coding • Organisational Performance & Predictive Analytics • Management Reporting • Alerts & target setti
Slide 16: Key Partnerships and International Expansion
Key Partnerships and International Expansion • Strategic partnership with Central Adelaide Local Health Network (CALHN) in South Australia to implement its decision support platform. • A strategic partnership with Southern DHB in New Zealand to implement proprietary data capture bar coding technolog
Slide 17: Collaborative Partnerships
Collaborative Partnerships As part of the acquisition of Potential(x), Beamtree now provides services to the following organisations. • Established in 2013, Ability Roundtable is a not-for-profit benchmarking and knowledge-sharing organisation in the disability sector. • Continued service improvemen
Slide 18: New Products & Enhancements
New Products & Enhancements Growth in microbiology and pathology RippleDown® Artificial Intelligence (AI) decision support expanded into microbiology and pathology services in several new countries with channel partners Philips and Abbott. Improvements and enhancements Major new releases for RippleD
Slide 19: Driving Beamtree's future growth
Driving Beamtree’s future growth Transformation Domestic TAM $427m, Innovation International TAM $13.6bn Expansion Domestic TAM $310m, • Goals and objectives focussed Domestic TAM $100m, International TAM $10.1bn entirely on future creative thinking International TAM $3.8bn • Transformative directio
Slide 20: Media Mentions
Media Mentions "The beauty of the system is when you look at the New hospital system predicts the future of a patient's condition Oct 28, 2021 single ward say 30 https://www.9news.com.au/national/new-medical-system-for-hospitals-monitor- patients-warning-signs-new-south-wales/e1b8e92f-3b7b-4171-82f9
Slide 21: Thought Leadership & Collaboratives
Thought Leadership & Collaboratives Global Impact Committee Chaired by Mark Britnell, this advisory board includes 15 international healthcare leaders from Australia, Canada, UK, Ireland, USA, Singapore, India, Italy and Sweden. Following the first meeting in October, the committee is “Networking an
Slide 22: Financial Summary 1H FY22
Financial Summary 1H FY22
Slide 23: 1H FY22 – continued strong revenue growth
1H FY22 – continued strong revenue growth Comments $(,000) 1H FY22 1H FY21 YoY Var $ YoYVar% • Total Revenue growth of 91%, up to $7.1m supported by 23.5% organic revenue growth YoY (exc. Acquisitions) due to Subscription, License & Usage new contract wins and strong performance in advisory Revenue
Slide 24: Revenue Composition
Revenue Composition 1H FY22 % of Recurring Revenue Revenue Profile 15% 15% 3% $7.1m $7.1m 50% Revenue Revenue 32% 85% Subscription, License & Usage - recurring Recurring Non-recurring Data Analytics - recurring Coding Service - recurring Consultancy & Initial license fee Revenue Comments • Recurring
Slide 25: Annual Recurring Revenue Growth
Annual Recurring Revenue Growth Comments • Annual Recurring Revenue (ARR) has increased at a CAGR of 72% since 1H FY20 on statutory basis. $,000 • The acquisition of Potential(x) has substantially increased Beamtree’s ARR through data analytics by adding $9.2m as 16,814 at the half year. • Increase
Slide 26: Statutory Balance Sheet
Statutory Balance Sheet Comments $(,000) 31 Dec 2021 30 June 2021 • $6.5m of net cash – position remains strong Assets • Debtors balance increased by $3.1m compared to 30 June Current assets 2021. Debtor balance of Potential(x) contributes $1.8m to the total of which $1.6m related to Health Roundtab
Slide 27: Statutory Cashflow
Statutory Cashflow Comments $(,000) 1H FY22 Operating cashflow Receipts from customers (inclusive of GST) 6,644 • Net cash outflow is driven by timing in receiving $1.9m (USD Payments to suppliers and employees (inclusive of GST) (8,866) $1.4m) from completion of Saudi project (expect to receive in
Slide 28: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 15 February 2022. This presentation may contain statements that are, or may be deemed to be, forward looking s
Slide 29: Q&A
Q&A
Slide 30: Thank you for your attendance
Thank you for your attendance